Retuningof mouse NK cells after interference with MHC class I sensing adjusts self-tolerance but preserves anticancer response

Cancer Immunology Research

Volumn 4, Issue 2, 2016, Pages 113-123

  Wagner, Arnika Kathleen ^a   Wickström, Stina Linnea ^a   Tallerico, Rossana ^b   Salam, Sadia ^a   Lakshmikanth, Tadepally ^a   Brauner, Hanna ^a   Höglund, Petter ^a   Carbone, Ennio ^b   Johansson, Maria Helena ^a   Kärre, Klas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; KLRG1 PROTEIN, MOUSE; MEMBRANE ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CROSS LINKING; HOST CELL; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; RECEPTOR BLOCKING; SELF CONCEPT; TUMOR REJECTION; WILD TYPE; ANIMAL; CYTOTOXICITY; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 84962040501     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0001     Document Type: Article

References (48)

1. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-9.
2. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227-58.
3. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9:495-502.
4. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 1992;358:66-70.
5. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
7. Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97:3132-7.
8. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014;123:678-86.
9. Vahlne G, Lindholm K, Meier A, Wickström S, Lakshmikanth T, Brennan F, et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells eveninthe presence of IL-2. Eur J Immunol 2010;40:813-23.
10. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012;120:4317-23.
11. Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120:4324-33.
12. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010;12:724-33.
13. Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog 2014;19:133-41.
14. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008;143:641-53.
15. Davies JO, Stringaris K, Barrett AJ, Rezvani K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy 2014;16:1453-66.
16. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014;26:161-72.
17. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-42.
18. Brodin P, Kärre K, Höglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009;30:143-9.
19. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-23.
20. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-13.
21. Höglund P, Ljunggren HG, Ohlen C, Ahrlund-Richter L, Scangos G, Bieberich C, et al. Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med 1988;168:1469-74.
22. Höglund P, Öhlen C, Carbone E, Franksson L, Ljunggren HG, Latour A, et al. Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m-mice: nonresponsiveness controlledbybeta 2m-bone marrowinchimeric mice. Proc Natl Acad Sci U S A 1991;88:10332-6.
23. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
24. Johansson S, Johansson M, Rosmaraki E, Vahlne G, Mehr R, Salmon-Divon M, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005;201:1145-55.
25. Johansson MH, Bieberich C, Jay G, Kärre K, Höglund P. Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med 1997;186:353-64.
26. Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 2010;207:2073-9.
27. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 2010;207:2065-72.
28. Gays F, Unnikrishnan M, Shrestha S, Fraser KP, Brown AR, Tristram CM, et al. Themousetumor celllinesEL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin. J Immunol 2000;164:5094-102.
29. Franksson L, George E, Powis S, Butcher G, Howard J, Kärre K. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J Exp Med 1993;177:201-5.
30. Belanger S, Tu MM, Rahim MM, Mahmoud AB, Patel R, Tai LH, et al. Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice. Blood 2012;120:592-602.
31. Oberg L, Johansson S, Michaelsson J, Tomasello E, Vivier E, Kärre K, et al. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo-role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol 2004;34:1646-53.
32. Wickstrom SL, Oberg L, Karre K, Johansson MH. A genetic defect in mice that impairs missing self recognition despite evidence for normal maturation and MHC class I-dependent education of NK cells. J Immunol 2014;192:1577-86.
33. Brodin P, Lakshmikanth T, Kärre K, Höglund P. Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J Immunol 2012;188:2218-26.
34. Corral L, Hanke T, Vance RE, Cado D, Raulet DH. NK cell expression of the killercell lectin-like receptorG1(KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. Eur J Immunol 2000;30:920-30.
35. Höglund P, Glas R, Menard C, Kase A, Johansson MH, Franksson L, et al. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. Eur J Immunol 1998;28:370-8.
36. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009;361:478-88.
37. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001;98:11521-6.
38. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
39. Haas P, Loiseau P, Tamouza R, Cayuela JM, Moins-Teisserenc H, Busson M, et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood 2011;117:1021-9.
40. Sola C, Andre P, Lemmers C, Fuseri N, Bonnafous C, Blery M, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A 2009;106:12879-84.
41. Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-Esposti MA, et al. NKcell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol 2007;178:4764-70.
42. Grundemann C, Schwartzkopff S, Koschella M, Schweier O, Peters C, Voehringer D, et al. The NK receptor KLRG1 is dispensable for virusinduced NK and CD8+ T-cell differentiation and function in vivo. Eur J Immunol 2010;40:1303-14.
43. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37.
44. Bessoles S, Grandclement C, Alari-Pahissa E, Gehrig J, Jeevan-Raj B, Held W. Adaptations of natural killer cells to self-MHC class I. Front Immunol 2014;5:349.
45. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002;100:3825-7.
46. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-9.
47. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
48. Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014;124:4781-94.